blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3551211

EP3551211 - LEBECETIN, A C-TYPE LECTIN, AS NEOVASCULARIZATION INHIBITOR [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  08.07.2022
Database last updated on 03.10.2024
FormerThe patent has been granted
Status updated on  30.07.2021
FormerGrant of patent is intended
Status updated on  24.03.2021
FormerExamination is in progress
Status updated on  02.06.2020
FormerRequest for examination was made
Status updated on  13.09.2019
FormerThe international publication has been made
Status updated on  23.06.2018
Formerunknown
Status updated on  19.01.2018
Most recent event   Tooltip13.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 16.10.2024 [2024/42]
Applicant(s)For all designated states
Sorbonne Université
21, rue de L'École de Médecine
75006 Paris / FR
For all designated states
Centre National de la Recherche Scientifique
3, rue Michel-Ange
75016 Paris / FR
For all designated states
INSERM (Institut National de la Santé et de la Recherche Médicale)
101, rue de Tolbiac
75013 Paris / FR
For all designated states
INSTITUT PASTEUR DE TUNIS
13 place Pasteur
B.P. 74
1002 Tunis / TN
[2019/42]
Inventor(s)01 / GUILLONNEAU, Xavier
65 rue du Point du Jour
92100 Boulogne Billancourt / FR
02 / MONTASSAR, Fadoua
3 rue Gazan
75014 Paris / FR
03 / MARRAKCHI, Naziha
15 rue Salem Bouhajeb
El Menzah 8
Ariana 2037 / TN
04 / MESSADI, Erij
9 rue Mohamed Bourguiba Mutuelleville
Tunis 1002 / TN
05 / SENNLAUB, Florian
117 Boulevard Voltaire
75011 Paris / FR
06 / SAHEL, José-Alain
4, rue Dieulafoy
75013 Paris / FR
 [2019/42]
Representative(s)Cabinet Becker et Associés
25, rue Louis le Grand
75002 Paris / FR
[2019/42]
Application number, filing date17826163.212.12.2017
[2019/42]
WO2017EP82482
Priority number, dateEP2016030666112.12.2016         Original published format: EP 16306661
[2019/42]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018108945
Date:21.06.2018
Language:EN
[2018/25]
Type: A1 Application with search report 
No.:EP3551211
Date:16.10.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 21.06.2018 takes the place of the publication of the European patent application.
[2019/42]
Type: B1 Patent specification 
No.:EP3551211
Date:01.09.2021
Language:EN
[2021/35]
Search report(s)International search report - published on:EP21.06.2018
ClassificationIPC:A61K38/17, C07K14/46, C12N15/11, A61P27/02, A61P35/00
[2019/42]
CPC:
A61K38/1703 (EP,IL,US); A61P27/02 (EP,IL,KR,US); C07K14/4726 (KR);
A61K38/1866 (US); A61K45/06 (KR); A61P35/00 (EP,IL,KR,US);
C07K14/46 (EP,IL,US); C07K14/7056 (EP,IL,US); C12N15/86 (US);
A61K2300/00 (KR); A61K38/00 (KR) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/42]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:LEBECETIN, EIN C-TYP-LEKTIN, ALS NEOVASKULARISATIONSINHIBITOR[2019/42]
English:LEBECETIN, A C-TYPE LECTIN, AS NEOVASCULARIZATION INHIBITOR[2019/42]
French:LEBECÉTINE, LECTINE DE TYPE C, COMME INHIBITEUR DE NÉOVASCULARISATION[2021/14]
Former [2019/42]LEBECETINE, LECTINE DE TYPE C, EN TANT QU'INHIBITEUR DE NÉOVASCULARISATION
Entry into regional phase04.07.2019National basic fee paid 
04.07.2019Designation fee(s) paid 
04.07.2019Examination fee paid 
Examination procedure04.07.2019Examination requested  [2019/42]
04.07.2019Date on which the examining division has become responsible
11.03.2020Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time
11.03.2020Despatch of communication of loss of particular rights: Claims {1}
15.05.2020Amendment by applicant (claims and/or description)
05.06.2020Despatch of a communication from the examining division (Time limit: M06)
10.12.2020Reply to a communication from the examining division
25.03.2021Communication of intention to grant the patent
21.07.2021Fee for grant paid
21.07.2021Fee for publishing/printing paid
21.07.2021Receipt of the translation of the claim(s)
Opposition(s)02.06.2022No opposition filed within time limit [2022/32]
Request for further processing for:15.05.2020Request for further processing filed
15.05.2020Full payment received (date of receipt of payment)
Request granted
28.05.2020Decision despatched
Fees paidRenewal fee
10.12.2019Renewal fee patent year 03
10.12.2020Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU12.12.2017
AL01.09.2021
AT01.09.2021
CY01.09.2021
CZ01.09.2021
DK01.09.2021
EE01.09.2021
FI01.09.2021
HR01.09.2021
LT01.09.2021
LV01.09.2021
MC01.09.2021
MK01.09.2021
MT01.09.2021
NL01.09.2021
PL01.09.2021
RO01.09.2021
RS01.09.2021
SE01.09.2021
SI01.09.2021
SK01.09.2021
SM01.09.2021
BG01.12.2021
NO01.12.2021
GR02.12.2021
LU12.12.2021
BE31.12.2021
IS01.01.2022
PT03.01.2022
[2024/42]
Former [2024/23]HU12.12.2017
AL01.09.2021
AT01.09.2021
CY01.09.2021
CZ01.09.2021
DK01.09.2021
EE01.09.2021
FI01.09.2021
HR01.09.2021
LT01.09.2021
LV01.09.2021
MC01.09.2021
MK01.09.2021
NL01.09.2021
PL01.09.2021
RO01.09.2021
RS01.09.2021
SE01.09.2021
SI01.09.2021
SK01.09.2021
SM01.09.2021
BG01.12.2021
NO01.12.2021
GR02.12.2021
LU12.12.2021
BE31.12.2021
IS01.01.2022
PT03.01.2022
Former [2023/33]HU12.12.2017
AL01.09.2021
AT01.09.2021
CY01.09.2021
CZ01.09.2021
DK01.09.2021
EE01.09.2021
FI01.09.2021
HR01.09.2021
LT01.09.2021
LV01.09.2021
MC01.09.2021
NL01.09.2021
PL01.09.2021
RO01.09.2021
RS01.09.2021
SE01.09.2021
SI01.09.2021
SK01.09.2021
SM01.09.2021
BG01.12.2021
NO01.12.2021
GR02.12.2021
LU12.12.2021
BE31.12.2021
IS01.01.2022
PT03.01.2022
Former [2023/30]AL01.09.2021
AT01.09.2021
CY01.09.2021
CZ01.09.2021
DK01.09.2021
EE01.09.2021
FI01.09.2021
HR01.09.2021
LT01.09.2021
LV01.09.2021
MC01.09.2021
NL01.09.2021
PL01.09.2021
RO01.09.2021
RS01.09.2021
SE01.09.2021
SI01.09.2021
SK01.09.2021
SM01.09.2021
BG01.12.2021
NO01.12.2021
GR02.12.2021
LU12.12.2021
BE31.12.2021
IS01.01.2022
PT03.01.2022
Former [2023/01]AL01.09.2021
AT01.09.2021
CZ01.09.2021
DK01.09.2021
EE01.09.2021
FI01.09.2021
HR01.09.2021
LT01.09.2021
LV01.09.2021
MC01.09.2021
NL01.09.2021
PL01.09.2021
RO01.09.2021
RS01.09.2021
SE01.09.2021
SI01.09.2021
SK01.09.2021
SM01.09.2021
BG01.12.2021
NO01.12.2021
GR02.12.2021
LU12.12.2021
BE31.12.2021
IS01.01.2022
PT03.01.2022
Former [2022/46]AL01.09.2021
AT01.09.2021
CZ01.09.2021
DK01.09.2021
EE01.09.2021
FI01.09.2021
HR01.09.2021
LT01.09.2021
LV01.09.2021
MC01.09.2021
NL01.09.2021
PL01.09.2021
RO01.09.2021
RS01.09.2021
SE01.09.2021
SI01.09.2021
SK01.09.2021
SM01.09.2021
BG01.12.2021
NO01.12.2021
GR02.12.2021
LU12.12.2021
IS01.01.2022
PT03.01.2022
Former [2022/36]AL01.09.2021
AT01.09.2021
CZ01.09.2021
DK01.09.2021
EE01.09.2021
FI01.09.2021
HR01.09.2021
LT01.09.2021
LV01.09.2021
MC01.09.2021
NL01.09.2021
PL01.09.2021
RO01.09.2021
RS01.09.2021
SE01.09.2021
SI01.09.2021
SK01.09.2021
SM01.09.2021
BG01.12.2021
NO01.12.2021
GR02.12.2021
IS01.01.2022
PT03.01.2022
Former [2022/33]AL01.09.2021
AT01.09.2021
CZ01.09.2021
EE01.09.2021
FI01.09.2021
HR01.09.2021
LT01.09.2021
LV01.09.2021
MC01.09.2021
NL01.09.2021
PL01.09.2021
RO01.09.2021
RS01.09.2021
SE01.09.2021
SK01.09.2021
SM01.09.2021
BG01.12.2021
NO01.12.2021
GR02.12.2021
IS01.01.2022
PT03.01.2022
Former [2022/29]AL01.09.2021
AT01.09.2021
CZ01.09.2021
EE01.09.2021
FI01.09.2021
HR01.09.2021
LT01.09.2021
LV01.09.2021
NL01.09.2021
PL01.09.2021
RO01.09.2021
RS01.09.2021
SE01.09.2021
SK01.09.2021
SM01.09.2021
BG01.12.2021
NO01.12.2021
GR02.12.2021
IS01.01.2022
PT03.01.2022
Former [2022/25]AT01.09.2021
CZ01.09.2021
EE01.09.2021
FI01.09.2021
HR01.09.2021
LT01.09.2021
LV01.09.2021
NL01.09.2021
PL01.09.2021
RO01.09.2021
RS01.09.2021
SE01.09.2021
SK01.09.2021
SM01.09.2021
BG01.12.2021
NO01.12.2021
GR02.12.2021
IS01.01.2022
PT03.01.2022
Former [2022/24]AT01.09.2021
CZ01.09.2021
EE01.09.2021
FI01.09.2021
HR01.09.2021
LT01.09.2021
LV01.09.2021
NL01.09.2021
PL01.09.2021
RO01.09.2021
RS01.09.2021
SE01.09.2021
SK01.09.2021
BG01.12.2021
NO01.12.2021
GR02.12.2021
IS01.01.2022
PT03.01.2022
Former [2022/21]AT01.09.2021
FI01.09.2021
HR01.09.2021
LT01.09.2021
LV01.09.2021
PL01.09.2021
RS01.09.2021
SE01.09.2021
BG01.12.2021
NO01.12.2021
GR02.12.2021
Former [2022/10]FI01.09.2021
HR01.09.2021
LT01.09.2021
LV01.09.2021
PL01.09.2021
RS01.09.2021
SE01.09.2021
BG01.12.2021
NO01.12.2021
GR02.12.2021
Former [2022/09]FI01.09.2021
LT01.09.2021
RS01.09.2021
SE01.09.2021
BG01.12.2021
NO01.12.2021
Former [2022/08]FI01.09.2021
LT01.09.2021
SE01.09.2021
BG01.12.2021
NO01.12.2021
Former [2022/07]LT01.09.2021
NO01.12.2021
Cited inInternational search[Y]WO2012154894  (ALLEGRO PHARMACEUTICALS INC [US], et al) [Y] 1-20 * the whole document ** claims 1, 23-31 *;
 [XP]  - FADOUA MONTASSAR ET AL, "Lebecetin, a C-type lectin, inhibits choroidal and retinal neovascularization", THE FASEB JOURNAL, US, (20161214), vol. 31, no. 3, doi:10.1096/fj.201600351R, ISSN 0892-6638, pages 1107 - 1119, XP055359263 [XP] 1-20 * the whole document *

DOI:   http://dx.doi.org/10.1096/fj.201600351R
 [XP]  - CATHERINE EGAN ET AL, "The United Kingdom Diabetic Retinopathy Electronic Medical Record Users Group, Report 1: baseline characteristics and visual acuity outcomes in eyes treated with intravitreal injections of ranibizumab for diabetic macular oedema", BRITISH JOURNAL OF OPHTHALMOLOGY, GB, (20161213), vol. 101, no. 1, doi:10.1136/bjophthalmol-2016-309313, ISSN 0007-1161, pages 75 - 80, XP055359268 [XP] 1-20 * Lebecetin, a C-type lectin, inhibits choroidal and retinal neovascularization; page 10 *

DOI:   http://dx.doi.org/10.1136/bjophthalmol-2016-309313
 [Y]  - SARRAY ET AL, "Lebectin and lebecetin, two C-type lectins from snake venom, inhibit alpha5beta1 and alphav-containing integrins", MATRIX BIOLOGY, ELSEVIER, NL, (20070501), vol. 26, no. 4, doi:10.1016/J.MATBIO.2007.01.001, ISSN 0945-053X, pages 306 - 313, XP022054746 [Y] 1-20 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.matbio.2007.01.001
 [Y]  - ANTHONY PILORGET ET AL, "Lebectin, aMacrovipera lebetina venom-derived C-type lectin, inhibits angiogenesis both in vitro and in vivo", JOURNAL OF CELLULAR PHYSIOLOGY, US, (20070101), vol. 211, no. 2, doi:10.1002/jcp.20935, ISSN 0021-9541, pages 307 - 315, XP055359264 [Y] 1-20 * the whole document *

DOI:   http://dx.doi.org/10.1002/jcp.20935
 [Y]  - JED JEBALI ET AL, "Expression of a functional recombinant C-type lectin-like protein lebecetin in the human embryonic kidney cells", BIOTECHNOLOGY PROGRESS., US, (20121019), vol. 28, no. 6, doi:10.1002/btpr.1632, ISSN 8756-7938, pages 1560 - 1565, XP055359275 [Y] 1-20 * the whole document *

DOI:   http://dx.doi.org/10.1002/btpr.1632
 [Y]  - JEBALI JED ET AL, "Lebecin, a new C-type lectin like protein fromMacrovipera lebetinavenom with anti-tumor activity against the breast cancer cell line MDA-MB231", TOXICON, (2014), vol. 86, doi:10.1016/J.TOXICON.2014.04.010, ISSN 0041-0101, pages 16 - 27, XP028873533 [Y] 1-20 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.toxicon.2014.04.010
 [Y]  - JEBALI J ET AL, "C-type lectin protein isoforms of Macrovipera lebetina: cDNA cloning and genetic diversity", TOXICON, ELMSFORD, NY, US, vol. 53, no. 2, doi:10.1016/J.TOXICON.2008.11.006, ISSN 0041-0101, (20090201), pages 228 - 237, (20081124), XP025873945 [Y] 1-20 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.toxicon.2008.11.006
 [Y]  - K. BAILEY FREUND ET AL, "Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration", CLINICAL OPHTHALMOLOGY, (20151201), doi:10.2147/OPTH.S80040, page 2355, XP055359313 [Y] 1-20 * the whole document *

DOI:   http://dx.doi.org/10.2147/OPTH.S80040
 [Y]  - MAKOTO ISHIKAWA ET AL, "Future Therapies of Wet Age-Related Macular Degeneration", JOURNAL OF OPHTHALMOLOGY, US, (20150101), vol. 2015, doi:10.1155/2015/138070, ISSN 2090-004X, pages 1 - 10, XP055359615 [Y] 1-20 * the whole document * * page 4, column r, paragraph 3 *

DOI:   http://dx.doi.org/10.1155/2015/138070
 [Y]  - SARRAY S ET AL, "Lebecetin, a potent antiplatelet C-type lectin from Macrovipera lebetina venom", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - PROTEINS & PROTEOMICS, ELSEVIER, NETHERLANDS, (20030923), vol. 1651, no. 1-2, doi:10.1016/S1570-9639(03)00232-2, ISSN 1570-9639, pages 30 - 40, XP004456089 [Y] 1-20 * the whole document *

DOI:   http://dx.doi.org/10.1016/S1570-9639(03)00232-2
by applicantWO0183692
 US2007184015
    - HOWARTH, Cell Biol Toxicol, (20100000), vol. 26, pages 1 - 10
    - DALKARA D et al., Gene Ther., (20120200), vol. 19, no. 2, pages 176 - 81
    - DALKARA D et al., Sci Transl Mes., (20130612), vol. 5, no. 189, page 189ra76
    - BERGER, A.; CAVALLERO, S.; DOMINGUEZ, E.; BARBE, P.; SIMONUTTI, M.; SAHEL, J.-A.; SENNLAUB, F.; RAOUL, W.; PAQUES, M.; BEMELMANS,, "Spectral-Domain Optical Coherence Tomography of the Rodent Eye: Highlighting Layers of the Outer Retina Using Signal Averaging and Comparison with Histology", PLoS One, (20140000), vol. 9, page e96494
    - BISHOP, P. N., "The role of extracellular matrix in retinal vascular development and preretinal neovascularization", Exp. Eye Res., (20150000), vol. 133, doi:doi:10.1016/j.exer.2014.10.021, pages 30 - 36, XP029209744

DOI:   http://dx.doi.org/10.1016/j.exer.2014.10.021
    - BROOKS, P. C.; MONTGOMERY, A. M.; ROSENFELD, M.; REISFELD, R. A.; HU, T.; KLIER, G.; CHERESH, D. A., "Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels", Cell, (19940000), vol. 79, pages 1157 - 1164
    - BROWN, D. M.; KAISER, P. K.; MICHELS, M.; SOUBRANE, G.; HEIER, J. S.; KIM, R. Y.; SY, J. P.; SCHNEIDER, S., "ANCHOR Study Group. (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration", N. Engl. J. Med., vol. 355, pages 1432 - 1444
    - CONNOR, K. M.; KRAH, N. M.; DENNISON, R. J.; ADERMAN, C. M.; CHEN, J.; GUERIN, K. I.; SAPIEHA, P.; STAHL, A.; WILLETT, K. L.; SMIT, "Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis", Nat. Protoc., (20090000), vol. 4, pages 1565 - 1573
    - D'AMORE, P. A., "Mechanisms of retinal and choroidal neovascularization", Invest. Ophthalmol. Vis. Sci., (19940000), vol. 35, pages 3974 - 3979, XP000574860
    - DOMINGUEZ, E.; RAOUL, W.; CALIPPE, B.; SAHEL, J.-A.; GUILLONNEAU, X.; PAQUES, M.; SENNLAUB, F., "Experimental Branch Retinal Vein Occlusion Induces Upstream Pericyte Loss and Vascular Destabilization", PLoS One, (20150000), vol. 10, page e0132644
    - EGH0J, M. S.; S0RENSEN, T. L., "Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab", Br. J. Ophthalmol., (20120000), vol. 96, pages 21 - 23
    - FOROOGHIAN, F.; CUKRAS, C.; MEYERLE, C. B.; CHEW, E. Y.; WONG, W. T., "Tachyphylaxis Following Intravitreal Bevacizumab for Exudative Age-Related Macular Degeneration", Retina Phila. Pa, (20090000), vol. 29, pages 723 - 731
    - FRIEDLANDER, M.; BROOKS, P. C.; SHAFFER, R. W.; KINCAID, C. M.; VARNER, J. A.; CHERESH, D. A., "Definition of two angiogenic pathways by distinct alpha v integrins", Science, (19950000), vol. 270, pages 1500 - 1502
    - FRIEDLANDER, M.; THEESFELD, C. L.; SUGITA, M.; FRUTTIGER, M.; THOMAS, M. A.; CHANG, S.; CHERESH, D. A., "Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases", Proc. Natl. Acad. Sci. U. S. A., (19960000), vol. 93, pages 9764 - 9769, XP002656145
    - "Prevalence of age-related macular degeneration in the United States", FRIEDMAN, D. S.; O'COLMAIN, B. J.; MUNOZ, B.; TOMANY, S. C.; MCCARTY, C.; DE JONG, P. T. V. M.; NEMESURE, B.; MITCHELL, P.; KEMPEN, Arch. Ophthalmol. Chic. !!! 1960, Eye Diseases Prevalence Research Group, (20040000), vol. 122, pages 564 - 572
    - FU, Y.; PONCE, M. L.; THILL, M.; YUAN, P.; WANG, N. S.; CSAKY, K. G., "Angiogenesis inhibition and choroidal neovascularization suppression by sustained delivery of an integrin antagonist, EMD478761", Invest. Ophthalmol. Vis. Sci., (20070000), vol. 48, pages 5184 - 5190
    - GOODMAN, S. L.; PICARD, M., "Integrins as therapeutic targets", Trends Pharmacol. Sci., (20120000), vol. 33, doi:doi:10.1016/j.tips.2012.04.002, pages 405 - 412, XP028495741

DOI:   http://dx.doi.org/10.1016/j.tips.2012.04.002
    - HONDA, S.; NAGAI, T.; NEGI, A., "Anti-angiogenic effects of non-peptide integrin alphavbeta3 specific antagonist on laser-induced choroidal neovascularization in mice", Graefes Arch. Clin. Exp. Ophthalmol. Albrecht Von Graefes Arch. Fur Klin. Exp. Ophthalmol., (20090000), vol. 247, pages 515 - 522, XP019714650
    - JEBALI J; BAZAA A; SARRAY S; BENHAJ K; KARBOUL A; EL AYEB M; MARRAKCHI N; GARGOURI A, "C-type lectin protein isoforms of Macrovipera lebetina: cDNA cloning and genetic diversity", Toxicon., (20090200), vol. 53, no. 2, doi:doi:10.1016/j.toxicon.2008.11.006, pages 228 - 37, XP025873945

DOI:   http://dx.doi.org/10.1016/j.toxicon.2008.11.006
    - JEBALI J.; JEANNEAU C.; MORJEN M.; MATHIEU S.; BAZAA A.; EL AYEB M.; LUIS J.; GARGOURI A.; MARRAKCHI N.; EL BATTARI A., "Expression of a functional recombinant C-type lectin-like protein lebecetin in the human embryonic kidney cells", Biotechnol Prog., (20121100), vol. 28, no. 6, doi:doi:10.1002/btpr.1632, pages 1560 - 5, XP055359275

DOI:   http://dx.doi.org/10.1002/btpr.1632
    - "The prevalence of diabetic retinopathy among adults in the United States", KEMPEN, J. H.; O'COLMAIN, B. J.; LESKE, M. C.; HAFFNER, S. M.; KLEIN, R.; MOSS, S. E.; TAYLOR, H. R.; HAMMAN, R. F., Arch. Ophthalmol. Chic. !!!, Eye Diseases Prevalence Research Group, (19600000), vol. 122, pages 552 - 563
    - KLEIN, R.; PETO, T.; BIRD, A.; VANNEWKIRK, M. R., "The epidemiology of age-related macular degeneration", Am. J. Ophthalmol., (20040000), vol. 137, doi:doi:10.1016/j.ajo.2003.11.069, pages 486 - 495, XP004755593

DOI:   http://dx.doi.org/10.1016/j.ajo.2003.11.069
    - LAMBERT, V.; LECOMTE, J.; HANSEN, S.; BLACHER, S.; GONZALEZ, M.-L. A.; STRUMAN, I.; SOUNNI, N. E.; ROZET, E.; DE TULLIO, P.; FOIDA, "Laser-induced choroidal neovascularization model to study age-related macular degeneration in mice", Nat. Protoc., (20130000), vol. 8, pages 2197 - 2211
    - LAUNAY, P.-S.; REBOUSSIN, E.; LIANG, H.; KESSAL, K.; GODEFROY, D.; ROSTENE, W.; SAHEL, J.-A.; BAUDOUIN, C., "Melik Parsadaniantz, S., and Reaux Le Goazigo, A. (2016) Ocular inflammation induces trigeminal pain, peripheral and central neuroinflammatory mechanisms", Neurobiol. Dis., vol. 88, pages 16 - 28
    - LAVALETTE, S.; RAOUL, W.; HOUSSIER, M.; CAMELO, S.; LEVY, O.; CALIPPE, B.; JONET, L.; BEHAR-COHEN, F.; CHEMTOB, S.; GUILLONNEAU, X, "Interleukin-ip Inhibition Prevents Choroidal Neovascularization and Does Not Exacerbate Photoreceptor Degeneration", Am. J. Pathol., (20110000), vol. 178, pages 2416 - 2423
    - MARTINEZ-ZAPATA, M. J.; MARTF-CARVAJAL, A. J.; SOLA, I.; PIJOAN, J. I.; BUIL-CALVO, J. A.; CORDERO, J. A.; EVANS, J. R., "Anti-vascular endothelial growth factor for proliferative diabetic retinopathy", Cochrane Database Syst. Rev., (20140000), vol. 11
    - NAKAJIMA, T.; HIRATA, M.; SHEARER, T. R.; AZUMA, M., "Mechanism for laser-induced neovascularization in rat choroid: Accumulation of integrin a chain-positive cells and their ligands", Mol. Vis., (20140000), vol. 20, pages 864 - 871
    - PAPADOPOULOS, N.; MARTIN, J.; RUAN, Q.; RAFIQUE, A.; ROSCONI, M. P.; SHI, E.; PYLES, E. A.; YANCOPOULOS, G. D.; STAHL, N.; WIEGAND, "Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab", Angiogenesis, (20120000), vol. 15, doi:doi:10.1007/s10456-011-9249-6, pages 171 - 185, XP035048394

DOI:   http://dx.doi.org/10.1007/s10456-011-9249-6
    - PILORGET, A.; CONESA, M.; SARRAY, S.; MICHAUD-LEVESQUE, J.; DAOUD, S.; KIM, K. S.; DEMEULE, M.; MARVALDI, J.; EL AYEB, M.; MARRAKC, "Lebectin, a Macrovipera lebetina venom-derived C-type lectin, inhibits angiogenesis both in vitro and in vivo", J. Cell. Physiol., (20070000), vol. 211, doi:doi:10.1002/jcp.20935, pages 307 - 315, XP055359264

DOI:   http://dx.doi.org/10.1002/jcp.20935
    - REMTULLA, S.; HALLETT, P. E., "A schematic eye for the mouse, and comparisons with the rat", Vision Res., (19850000), vol. 25, doi:doi:10.1016/0042-6989(85)90076-8, pages 21 - 31, XP024310856

DOI:   http://dx.doi.org/10.1016/0042-6989(85)90076-8
    - ROBBINS, S. G.; BREM, R. B.; WILSON, D. J.; O'ROURKE, L. M.; ROBERTSON, J. E.; WESTRA, I.; PLANCK, S. R.; ROSENBAUM, J. T., "Immunolocalization of integrins in proliferative retinal membranes", Invest. Ophthalmol. Vis. Sci., (19940000), vol. 35, pages 3475 - 3485
    - "Ranibizumab for neovascular age-related macular degeneration", ROSENFELD, P. J.; BROWN, D. M.; HEIER, J. S.; BOYER, D. S.; KAISER, P. K.; CHUNG, C. Y.; KIM, R. Y., N. Engl. J. Med., MARINA Study Group, (20060000), vol. 355, pages 1419 - 1431
    - SALEHI-HAD, H.; ROH, M. I.; GIANI, A.; HISATOMI, T.; NAKAO, S.; KIM, I. K.; GRAGOUDAS, E. S.; VAVVAS, D.; GUCCIONE, S.; MILLER, J., "Utilizing Targeted Gene Therapy with Nanoparticles Binding Alpha v Beta 3 for Imaging and Treating Choroidal Neovascularization", PLoS One, (20110000), vol. 6, page e18864
    - SARRAY, S.; SRAIRI, N.; HATMI, M.; LUIS, J.; LOUZIR, H.; REGAYA, I.; SLEMA, H.; MARVALDI, J.; EL AYEB, M.; MARRAKCHI, N., "Lebecetin, a potent antiplatelet C-type lectin from Macrovipera lebetina venom", Biochim. Biophys. Acta, (20030000), vol. 1651, doi:doi:10.1016/S1570-9639(03)00232-2, pages 30 - 40, XP004456089

DOI:   http://dx.doi.org/10.1016/S1570-9639(03)00232-2
    - SARRAY, S.; DELAMARRE, E.; MARVALDI, J.; EL AYEB, M.; MARRAKCHI, N.; LUIS, J., "Lebectin and lebecetin, two C-type lectins from snake venom, inhibit alpha5betal and alphaV-containing integrins", Matrix Biol. J. Int. Soc. Matrix Biol., (20070000), vol. 26, doi:doi:10.1016/j.matbio.2007.01.001, pages 306 - 313, XP022054746

DOI:   http://dx.doi.org/10.1016/j.matbio.2007.01.001
    - SCHINDELIN, J.; ARGANDA-CARRERAS, I.; FRISE, E.; KAYNIG, V.; LONGAIR, M.; PIETZSCH, T.; PREIBISCH, S.; RUEDEN, C.; SAALFELD, S.; S, "Fiji: an open-source platform for biological-image analysis", Nat. Methods, (20120000), vol. 9, doi:doi:10.1038/nmeth.2019, pages 676 - 682, XP055343835

DOI:   http://dx.doi.org/10.1038/nmeth.2019
    - SHAO, Z.; FRIEDLANDER, M.; HURST, C. G.; CUI, Z.; PEI, D. T.; EVANS, L. P.; JUAN, A. M.; TAHIR, H.; DUHAMEL, F.; CHEN, J., "Choroid Sprouting Assay: An Ex Vivo Model of Microvascular Angiogenesis", PLoS One, (20130000), vol. 8, page e69552
    - SMITH, L. E.; WESOLOWSKI, E.; MCLELLAN, A.; KOSTYK, S. K.; D'AMATO, R.; SULLIVAN, R.; D'AMORE, P. A., "Oxygen-induced retinopathy in the mouse", Invest. Ophthalmol. Vis. Sci., (19940000), vol. 35, pages 101 - 111, XP003014482
    - STAHL, A.; CONNOR, K. M.; SAPIEHA, P.; WILLETT, K. L.; KRAH, N. M.; DENNISON, R. J.; CHEN, J.; GUERIN, K. I.; SMITH, L. E. H., "Computer-aided quantification of retinal neovascularization", Angiogenesis, (20090000), vol. 12, doi:doi:10.1007/s10456-009-9155-3, pages 297 - 301, XP019745623

DOI:   http://dx.doi.org/10.1007/s10456-009-9155-3
    - TSUJINO, H.; KONDO, E.; FUKUOKA, T.; DAI, Y.; TOKUNAGA, A.; MIKI, K.; YONENOBU, K.; OCHI, T.; NOGUCHI, K., "Activating transcription factor 3 (ATF3) induction by axotomy in sensory and motoneurons: A novel neuronal marker of nerve injury", Mol. Cell. Neurosci., (20000000), vol. 15, pages 170 - 182
    - UMEDA, N.; KACHI, S.; AKIYAMA, H.; ZAHN, G.; VOSSMEYER, D.; STRAGIES, R.; CAMPOCHIARO, P. A., "Suppression and Regression of Choroidal Neovascularization by Systemic Administration of an α5β1 Integrin Antagonist", Mol. Pharmacol., (20060000), vol. 69, pages 1820 - 1828
    - WALENSKY L. D.; BIRD G. H., "Hydrocarbon-stapled peptides: principles, practice, and progress", J Med Chem., (20140814), vol. 57, no. 15, doi:doi:10.1021/jm4011675, pages 6275 - 88, XP055146896

DOI:   http://dx.doi.org/10.1021/jm4011675
    - WANG, W.; WANG, F.; LU, F.; XU, S.; HU, W.; HUANG, J.; GU, Q.; SUN, X., "The antiangiogenic effects of integrin alpha5betal inhibitor (ATN-161) in vitro and in vivo", Invest. Ophthalmol. Vis. Sci., (20110000), vol. 52, pages 7213 - 7220
    - ZAHN, G.; VOSSMEYER, D.; STRAGIES, R.; WILLS, M.; WONG, C. G.; LOFFLER, K. U.; ADAMIS, A. P.; KNOLLE, J., "Preclinical evaluation of the novel small-molecule integrin alpha5betal inhibitor JSM6427 in monkey and rabbit models of choroidal neovascularization", Arch. Ophthalmol. Chic. III, (19600000), vol. 127, pages 1329 - 1335
    - ZELENSKY et al., FEBS Journal, (20050000), vol. 272, pages 6179 - 6217
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.